TSE:MDNA

Medicenna Therapeutics - MDNA Stock Forecast, Price & News

C$2.27

+0.09 (+4.13%)

(As of 08/8/2022 12:00 AM ET)

Add

Compare

Today's Range: C$2.14
▼
C$2.38
50-Day Range: C$0.99
▼
C$2.27
52-Week Range: C$0.98
▼
C$3.67

Volume: 98,749 shs
Average Volume: 30,732 shs
Market Capitalization: C$127.81 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: C$8.50

About Medicenna Therapeutics (TSE:MDNA) Stock

Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.

Medicenna Therapeutics Stock Up 4.1 %

Shares of Medicenna Therapeutics stock opened at C$2.27 on Tuesday. The stock's fifty day moving average is C$1.54 and its 200-day moving average is C$1.64. The firm has a market capitalization of C$127.81 million and a PE ratio of -4.82. The company has a quick ratio of 8.33, a current ratio of 8.92 and a debt-to-equity ratio of 0.06. Medicenna Therapeutics has a 12-month low of C$0.98 and a 12-month high of C$3.67.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the company. HC Wainwright restated a "buy" rating and issued a C$5.00 price objective on shares of Medicenna Therapeutics in a report on Thursday, June 23rd. Maxim Group assumed coverage on Medicenna Therapeutics in a report on Wednesday, June 22nd. They set a "buy" rating and a C$4.00 target price on the stock. Bloom Burton restated a "buy" rating and set a C$11.00 price objective on shares of Medicenna Therapeutics in a report on Thursday, July 28th. Finally, Brookline Capital Acquisition lifted their target price on Medicenna Therapeutics to C$14.00 and gave the stock a "buy" rating in a research report on Wednesday, April 13th.

Receive MDNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medicenna Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MDNA Stock News Headlines

August 8, 2022 | finance.yahoo.com

Medicenna Announces the Launch of a Marketed Underwritten Public Offering of Units

August 1, 2022 | americanbankingnews.com

Medicenna Therapeutics (TSE:MDNA) Earns Buy Rating from Bloom Burton

June 9, 2022 | finance.yahoo.com

Medicenna Strengthens Intellectual Property Protection for Superkine Platform with Issuance of U.S. Patent

May 10, 2022 | finance.yahoo.com

Will Medicenna Therapeutics (TSE:MDNA) Spend Its Cash Wisely?

May 3, 2022 | seekingalpha.com

CIG, GRTX and MDNA among pre market gainers

April 27, 2022 | msn.com

MDNA: AACR Presentations Highlight Preclinical Data for Anti-PD1-IL-2 BiSKIT and IL-13 Super-Antagonist…

March 9, 2022 | finance.yahoo.com

Medicenna Announces Upcoming Poster Presentations at the AACR Annual Meeting

March 3, 2022 | finance.yahoo.com

Medicenna Announces Appointment of Clinical Advisory Board and Dr. Kapil Dhingra as Strategic Advisor

November 4, 2021 | finance.yahoo.com

Medicenna Therapeutics to Announce Second Quarter 2022 Financial Results and Operational Highlights on Friday, November 12, 2021

October 27, 2021 | msn.com

BRIEF-Medicenna Announces FDA Clearance Of Ind To Expand The Phase 1/2 Ability Study Of Mdna11 To The United States

October 27, 2021 | finance.yahoo.com

Medicenna Announces FDA Clearance of IND to Expand the Phase 1/2 ABILITY Study of MDNA11 to the United States

July 20, 2021 | finance.yahoo.com

We Think Medicenna Therapeutics (TSE:MDNA) Can Afford To Drive Business Growth

June 2, 2021 | finance.yahoo.com

MDNA: Phase 1 Trial of MDNA11 to Initiate in 3Q21…

May 7, 2021 | finance.yahoo.com

Medicenna Announces the Peer-Reviewed Publication of Clinical Data from Phase 2b Trial Evaluating MDNA55 in Recurrent Glioblastoma

April 14, 2021 | finance.yahoo.com

Medicenna to Present at the Bloom Burton & Co. Healthcare Investor Conference

January 10, 2021 | realmoney.thestreet.com

Medicenna Therapeutics Corp. (MDNA)

December 18, 2020 | msn.com

Why Sonoma, Medicenna And Dare Bioscience Are Trading Higher Today

December 4, 2020 | finance.yahoo.com

Companies Like Medicenna Therapeutics (TSE:MDNA) Are In A Position To Invest In Growth

October 30, 2020 | businesswire.com

Medidata Synthetic Control Arm® Supported by the US Food and Drug Administration (FDA) for Use in Medicenna Therapeutics, Corp. Phase 3 Registrational Trial in Recurrent ...

October 15, 2020 | markets.businessinsider.com

Medicenna Provides MDNA55 rGBM Clinical Program Update Following Positive End of Phase 2 Meeting with the U.S. Food and Drug Administration (FDA)

August 20, 2020 | finance.yahoo.com

Medicenna to Commence Trading on Nasdaq

August 16, 2020 | ca.finance.yahoo.com

Medicenna Therapeutics Corp. (MDNAF)

August 7, 2020 | finance.yahoo.com

MDNAF: End of Phase 2’ Meeting for MDNA55 in September 2020…

August 4, 2020 | finance.yahoo.com

Medicenna Reports First Quarter Fiscal 2021 Financial Results and Operational Highlights

June 11, 2020 | finance.yahoo.com

Medicenna to Present at Raymond James Human Healthcare Innovation Conference

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive MDNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medicenna Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MDNA Company Calendar

Today: 8/09/2022
Next Earnings (Estimated): 8/11/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: TSE
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: TSE:MDNA
CUSIP: N/A
CIK: N/A
Web: www.medicenna.com
Phone: +1-403-6807898
Fax: N/A
Employees: 13
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: C$8.50
High Stock Price Forecast: C$14.00
Low Stock Price Forecast: C$4.00
Forecasted Upside/Downside: +274.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 0.06
Current Ratio: 8.92
Quick Ratio: 8.33

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: C$0.42 per share
Price / Cash Flow: 5.37
Book Value: C$0.37 per share
Price / Book: 6.07

Miscellaneous

Outstanding Shares: 56,304,000
Free Float: N/A
Market Cap: C$127.81 million
Optionable: Not Optionable
Beta: N/A

Key Executives

Dr. Fahar Merchant Ph.D. (Age 65)
Founder, Chairman, Pres & CEO
Comp: $462.15k
Ms. Rosemina Merchant B.Sc. (Age 65)
M.E.Sc, Founder, Chief Devel. Officer & Director
Comp: $370.62k
Ms. Elizabeth Williams C.A. (Age 44)
CPA, CA, CPA, CFO & Corp. Sec.
Comp: $311k
Dr. Martin Bexon M.D.
MBBS, Acting Chief Medical Officer & Head of Clinical Devel.
Dr. Samuel R. Denmeade M.D.
Scientific Advisor

Key Competitors

View All Competitors

Insiders & Institutions

Elizabeth Williams
Bought 4,000 shares on 11/1/2021
Total: C$10,982.80 ($2.75/share)

View All Insider Transactions
View All Institutional Transactions

MDNA Stock - Frequently Asked Questions

Should I buy or sell Medicenna Therapeutics stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Medicenna Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MDNA shares.
View MDNA analyst ratings or view top-rated stocks.
What is Medicenna Therapeutics' stock price forecast for 2022?: 4 Wall Street analysts have issued twelve-month price targets for Medicenna Therapeutics' stock. Their MDNA share price forecasts range from C$4.00 to C$14.00. On average, they expect the company's share price to reach C$8.50 in the next twelve months. This suggests a possible upside of 274.4% from the stock's current price.
View analysts price targets for MDNA or view top-rated stocks among Wall Street analysts.
How has Medicenna Therapeutics' stock price performed in 2022?: Medicenna Therapeutics' stock was trading at C$2.10 at the beginning of the year. Since then, MDNA shares have increased by 8.1% and is now trading at C$2.27.
View the best growth stocks for 2022 here.
When is Medicenna Therapeutics' next earnings date?: Medicenna Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our MDNA earnings forecast.

What other stocks do shareholders of Medicenna Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Medicenna Therapeutics investors own include OPKO Health (OPK), AbbVie (ABBV), Livongo Health (LVGO), Aptose Biosciences (APTO), Birchcliff Energy (BIR), CVS Health (CVS), Freehold Royalties (FRU), Fastly (FSLY) and Inovio Pharmaceuticals (INO).
What is Medicenna Therapeutics' stock symbol?: Medicenna Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "MDNA."
How do I buy shares of Medicenna Therapeutics?: Shares of MDNA stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.
What is Medicenna Therapeutics' stock price today?: One share of MDNA stock can currently be purchased for approximately C$2.27.
How much money does Medicenna Therapeutics make?: Medicenna Therapeutics (TSE:MDNA) has a market capitalization of C$127.81 million.
How many employees does Medicenna Therapeutics have?: Medicenna Therapeutics employs 13 workers across the globe.
How can I contact Medicenna Therapeutics?: Medicenna Therapeutics' mailing address is 2440 Kensington Rd NW, CALGARY, AB T2N 3S1, Canada. The official website for the company is www.medicenna.com. The company can be reached via phone at +1-403-6807898.

This page (TSE:MDNA) was last updated on 8/9/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Medicenna Therapeutics - MDNA Stock Forecast, Price & News

About Medicenna Therapeutics (TSE:MDNA) Stock

Medicenna Therapeutics Stock Up 4.1 %

Wall Street Analyst Weigh In

MDNA Stock News Headlines

MDNA Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

MDNA Stock - Frequently Asked Questions

Should I buy or sell Medicenna Therapeutics stock right now?

What is Medicenna Therapeutics' stock price forecast for 2022?

How has Medicenna Therapeutics' stock price performed in 2022?

When is Medicenna Therapeutics' next earnings date?

What other stocks do shareholders of Medicenna Therapeutics own?

What is Medicenna Therapeutics' stock symbol?

How do I buy shares of Medicenna Therapeutics?

What is Medicenna Therapeutics' stock price today?

How much money does Medicenna Therapeutics make?

How many employees does Medicenna Therapeutics have?

How can I contact Medicenna Therapeutics?

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources